Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P51659

UPID:
DHB4_HUMAN

ALTERNATIVE NAMES:
17-beta-hydroxysteroid dehydrogenase 4; D-bifunctional protein; Multifunctional protein 2; Short chain dehydrogenase/reductase family 8C member 1

ALTERNATIVE UPACC:
P51659; B4DNV1; B4DVS5; E9PB82; F5HE57

BACKGROUND:
Peroxisomal multifunctional enzyme type 2, known for its roles as 17-beta-hydroxysteroid dehydrogenase 4, D-bifunctional protein, and Multifunctional protein 2, is pivotal in the degradation of fatty acids within the peroxisomal beta-oxidation pathway. It efficiently catalyzes the hydration and dehydrogenation of fatty acids, producing 3-ketoacyl-CoA, a critical intermediate in fatty acid metabolism. Its substrate range includes both straight-chain and branched-chain fatty acids, as well as bile acid intermediates, showcasing its broad metabolic significance.

THERAPEUTIC SIGNIFICANCE:
Linked to critical health conditions such as D-bifunctional protein deficiency and Perrault syndrome 1, the enzyme's malfunction presents a significant therapeutic target. Exploring the multifaceted role of Peroxisomal multifunctional enzyme type 2 in these diseases could lead to groundbreaking therapeutic interventions, marking a significant stride.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.